Table 2.
Main characteristics of all studies included in the meta-analysis for EGFR.
| References | Year | Origin | Case-controls | Antibody source | Dilution | Cut-off value |
|---|---|---|---|---|---|---|
| Rakha et al. [1] | 2007 | UK | 249/1293 | Novocastra | 1 : 10 | >10% |
| Gasparini et al. [10] | 2014 | USA | 381/262 | Dako | 1 : 100 | >10% |
| Tang et al. [14] | 2012 | China | 40/158 | Dako | Not available | >0% |
| Koo and Jung [24] | 2011 | Korea | 8/109 | Novocastra | 1 : 50 | >10% |
| Nogi et al. [33] | 2009 | Japan | 26/85 | Novocastra | Not available | >0% |
| Nozoe et al. [34] | 2011 | Japan | 7/30 | Dako | 1 : 10 | >10% |
| Pillai et al. [35] | 2012 | Malaysia | 18/18 | Dako | 1 : 50 | >1% |
| Rydén et al. [36] | 2010 | Sweden | 87/299 | Dako | Prediluted | >1% |
| Tan et al. [37] | 2008 | UK | 31/209 | Zymed | 1 : 50 | Not available |
| Tawfik et al. [38] | 2010 | USA | 151/379 | Zymed | 1 : 20 | Not available |